Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission

J. Tanaka, Y. Morishima, Y. Takahashi, T. Yabe, K. Oba, S. Takahashi, S. Taniguchi, H. Ogawa, Y. Onishi, K. Miyamura, H. Kanamori, N. Aotsuka, K. Kato, S. Kato, Y. Atsuta, Y. Kanda

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

To clarify the effect of killer cell immunoglobulin-like receptor (KIR) ligand incompatibility on outcomes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients in complete remission after single cord blood transplantation (CBT), we assessed the outcomes of CBT registered in the Japan Society for Hematopoietic Cell Transplantation (JSHCT) database. A total of 643 acute leukemia (357 AML and 286 ALL) patient and donor pairs were categorized according to their KIR ligand incompatibility by determining whether or not they expressed HLA-C, Bw4 or A3/A11 by DNA typing. A total of 128 patient-donor pairs were KIR ligand-incompatible in the graft-versus-host (GVH) direction and 139 patient-donor pairs were incompatible in the host-versusgraft (HVG) direction. Univariate and multivariate analyses showed no significant differences between the KIR ligand-incompatible and compatible groups in the GVH direction for both AML and ALL patients of overall survival, disease-free survival, relapse incidence, non-relapse mortality and acute GVH disease. However, KIR incompatibility in the HVG direction ameliorated engraftment in ALL patients (hazard ratio 0.66, 95% confidence interval 0.47-0.91, P=0.013). Therefore, there were no effects of KIR ligand incompatibility in the GVH direction on single CBT outcomes for acute leukemia patients without anti-thymocyte globulin use. However, it is necessary to pay attention to KIR incompatibility in the HVG direction for engraftment.

Original languageEnglish
Article numbere164
JournalBlood Cancer Journal
Volume3
Issue number11
DOIs
Publication statusPublished - Dec 3 2013
Externally publishedYes

Fingerprint

KIR Receptors
Fetal Blood
Leukemia
Transplantation
Ligands
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Tissue Donors
Transplants
HLA-A3 Antigen
HLA-C Antigens
Antilymphocyte Serum
DNA Fingerprinting
Cell Transplantation
Graft vs Host Disease
Disease-Free Survival
Direction compound
Japan
Multivariate Analysis
Databases

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. / Tanaka, J.; Morishima, Y.; Takahashi, Y.; Yabe, T.; Oba, K.; Takahashi, S.; Taniguchi, S.; Ogawa, H.; Onishi, Y.; Miyamura, K.; Kanamori, H.; Aotsuka, N.; Kato, K.; Kato, S.; Atsuta, Y.; Kanda, Y.

In: Blood Cancer Journal, Vol. 3, No. 11, e164, 03.12.2013.

Research output: Contribution to journalArticle

Tanaka, J, Morishima, Y, Takahashi, Y, Yabe, T, Oba, K, Takahashi, S, Taniguchi, S, Ogawa, H, Onishi, Y, Miyamura, K, Kanamori, H, Aotsuka, N, Kato, K, Kato, S, Atsuta, Y & Kanda, Y 2013, 'Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission', Blood Cancer Journal, vol. 3, no. 11, e164. https://doi.org/10.1038/bcj.2013.62
Tanaka, J. ; Morishima, Y. ; Takahashi, Y. ; Yabe, T. ; Oba, K. ; Takahashi, S. ; Taniguchi, S. ; Ogawa, H. ; Onishi, Y. ; Miyamura, K. ; Kanamori, H. ; Aotsuka, N. ; Kato, K. ; Kato, S. ; Atsuta, Y. ; Kanda, Y. / Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. In: Blood Cancer Journal. 2013 ; Vol. 3, No. 11.
@article{66865d3a29094f419582fa67ec0d33d8,
title = "Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission",
abstract = "To clarify the effect of killer cell immunoglobulin-like receptor (KIR) ligand incompatibility on outcomes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients in complete remission after single cord blood transplantation (CBT), we assessed the outcomes of CBT registered in the Japan Society for Hematopoietic Cell Transplantation (JSHCT) database. A total of 643 acute leukemia (357 AML and 286 ALL) patient and donor pairs were categorized according to their KIR ligand incompatibility by determining whether or not they expressed HLA-C, Bw4 or A3/A11 by DNA typing. A total of 128 patient-donor pairs were KIR ligand-incompatible in the graft-versus-host (GVH) direction and 139 patient-donor pairs were incompatible in the host-versusgraft (HVG) direction. Univariate and multivariate analyses showed no significant differences between the KIR ligand-incompatible and compatible groups in the GVH direction for both AML and ALL patients of overall survival, disease-free survival, relapse incidence, non-relapse mortality and acute GVH disease. However, KIR incompatibility in the HVG direction ameliorated engraftment in ALL patients (hazard ratio 0.66, 95{\%} confidence interval 0.47-0.91, P=0.013). Therefore, there were no effects of KIR ligand incompatibility in the GVH direction on single CBT outcomes for acute leukemia patients without anti-thymocyte globulin use. However, it is necessary to pay attention to KIR incompatibility in the HVG direction for engraftment.",
author = "J. Tanaka and Y. Morishima and Y. Takahashi and T. Yabe and K. Oba and S. Takahashi and S. Taniguchi and H. Ogawa and Y. Onishi and K. Miyamura and H. Kanamori and N. Aotsuka and K. Kato and S. Kato and Y. Atsuta and Y. Kanda",
year = "2013",
month = "12",
day = "3",
doi = "10.1038/bcj.2013.62",
language = "English",
volume = "3",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission

AU - Tanaka, J.

AU - Morishima, Y.

AU - Takahashi, Y.

AU - Yabe, T.

AU - Oba, K.

AU - Takahashi, S.

AU - Taniguchi, S.

AU - Ogawa, H.

AU - Onishi, Y.

AU - Miyamura, K.

AU - Kanamori, H.

AU - Aotsuka, N.

AU - Kato, K.

AU - Kato, S.

AU - Atsuta, Y.

AU - Kanda, Y.

PY - 2013/12/3

Y1 - 2013/12/3

N2 - To clarify the effect of killer cell immunoglobulin-like receptor (KIR) ligand incompatibility on outcomes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients in complete remission after single cord blood transplantation (CBT), we assessed the outcomes of CBT registered in the Japan Society for Hematopoietic Cell Transplantation (JSHCT) database. A total of 643 acute leukemia (357 AML and 286 ALL) patient and donor pairs were categorized according to their KIR ligand incompatibility by determining whether or not they expressed HLA-C, Bw4 or A3/A11 by DNA typing. A total of 128 patient-donor pairs were KIR ligand-incompatible in the graft-versus-host (GVH) direction and 139 patient-donor pairs were incompatible in the host-versusgraft (HVG) direction. Univariate and multivariate analyses showed no significant differences between the KIR ligand-incompatible and compatible groups in the GVH direction for both AML and ALL patients of overall survival, disease-free survival, relapse incidence, non-relapse mortality and acute GVH disease. However, KIR incompatibility in the HVG direction ameliorated engraftment in ALL patients (hazard ratio 0.66, 95% confidence interval 0.47-0.91, P=0.013). Therefore, there were no effects of KIR ligand incompatibility in the GVH direction on single CBT outcomes for acute leukemia patients without anti-thymocyte globulin use. However, it is necessary to pay attention to KIR incompatibility in the HVG direction for engraftment.

AB - To clarify the effect of killer cell immunoglobulin-like receptor (KIR) ligand incompatibility on outcomes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients in complete remission after single cord blood transplantation (CBT), we assessed the outcomes of CBT registered in the Japan Society for Hematopoietic Cell Transplantation (JSHCT) database. A total of 643 acute leukemia (357 AML and 286 ALL) patient and donor pairs were categorized according to their KIR ligand incompatibility by determining whether or not they expressed HLA-C, Bw4 or A3/A11 by DNA typing. A total of 128 patient-donor pairs were KIR ligand-incompatible in the graft-versus-host (GVH) direction and 139 patient-donor pairs were incompatible in the host-versusgraft (HVG) direction. Univariate and multivariate analyses showed no significant differences between the KIR ligand-incompatible and compatible groups in the GVH direction for both AML and ALL patients of overall survival, disease-free survival, relapse incidence, non-relapse mortality and acute GVH disease. However, KIR incompatibility in the HVG direction ameliorated engraftment in ALL patients (hazard ratio 0.66, 95% confidence interval 0.47-0.91, P=0.013). Therefore, there were no effects of KIR ligand incompatibility in the GVH direction on single CBT outcomes for acute leukemia patients without anti-thymocyte globulin use. However, it is necessary to pay attention to KIR incompatibility in the HVG direction for engraftment.

UR - http://www.scopus.com/inward/record.url?scp=84888408805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888408805&partnerID=8YFLogxK

U2 - 10.1038/bcj.2013.62

DO - 10.1038/bcj.2013.62

M3 - Article

AN - SCOPUS:84888408805

VL - 3

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 11

M1 - e164

ER -